Assoc. Prof. MUSTAFA MURAT ÖZBALAK

Publication Network

Articles 46

1. Kronik Lenfositik Lösemi Hastalarında CXCR5+CD8+ Foliküler Sitotoksik T hücreleri, CD8+ T hücreleri ve NK Hücrelerinde Perforin ve Granzim Seviyeleri

Gelmez M. Y., Öktelik F. B., Özbalak M. M., Yönal Hindilerden İ., Deniz G.

Acta Medica Nicomedia , vol.8, no.3, pp.308-313, 2025 (Peer-Reviewed Journal)

2. Kronik Lenfositik Lösemi Hastalarında Notch Ekspresyon Seviyeleri: Akan Hücre Ölçer ile Değerlendirilmesi

ÖKTELİK F. B., ÖZBALAK M. M., YÖNAL HİNDİLERDEN İ., DENİZ G., GELMEZ M. Y.

Acta Medica Nicomedia , vol.8, 2025 (Peer-Reviewed Journal)

3. Outcomes of patients with Hodgkin lymphoma receiving Brentuximab Vedotin (BV) as maintenance therapy after ASCT according to previous exposure to BV. A retrospective analysis of the EBMT Lymphoma Working Party in collaboration with GELTAMO, FIL, LYSA, and Turkish Lymphoma Group.

Martínez C., Khvedelidze I., Fekom M., Deau Fischer B., Marouf A., Ghesquières H., et al.

Bone marrow transplantation , 2025 (SCI-Expanded)

4. The Effect of T-Lymphocyte Subgroups at Diagnosis on The Prognosis of Chronic Lymphocytic Leukemia.

Seyithanoglu D., Sert E., Ozbalak M. M., Mastanzade M., Erdem S., Yenerel M. N.

Acta haematologica , pp.1-11, 2025 (SCI-Expanded)

5. Impact of COVID-19 on Hematologic Disorders: Clinical Insights and Challenges

ERDEM S., SERT EKİNCİ S., ÖZBALAK M. M., MASTANZADE M., YÖNAL HİNDİLERDEN İ., YENEREL M. N., et al.

Istanbul Medical Journal , vol.26, 2025 (ESCI)

6. Can BATF Expression Serve as a Predictive Marker for Treatment Necessity in Chronic Lymphocytic Leukemia?

GELMEZ M. Y., ÇINAR S., ADAY A., Ozcit G., Ozbalak M., Usta T., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , vol.35, no.3, pp.193-201, 2025 (SCI-Expanded, Scopus, TRDizin)

7. Congenital thrombotic thrombocytopenic purpura and human leukocyte antigen analysis-an amazing clue.

Kıkılı C. İ., Kıvanç D., Şentürk Çiftçi H., Özbalak M. M., Yenerel M. N., Nalçacı M., et al.

Hematology, transfusion and cell therapy , vol.47, no.1, pp.103746, 2025 (ESCI)

8. Central nervous system involvement of mantle cell lymphoma: Case report and review of the literature.

Ağargün B. F., Özbalak M. M., Gülseren Ü. A., Yegen G., Beşışık S.

Hematology, transfusion and cell therapy , vol.46, 2024 (ESCI, Scopus)

9. Long-Term Remission After Nelarabine and Donor Lymphocyte Infusion in a Patient With T-ALL Who Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation

Koruk K., Tiryaki T. O., ÖZBALAK M. M., MASTANZADE M., Arslan O., BEŞIŞIK S., et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , 2024 (SCI-Expanded)

10. Identification of HLA alleles involved in immune thrombotic thrombocytopenic purpura patients from Turkey.

Kıkılı C. İ., Kıvanç D., Ortaboz D., Şentürk Çiftçi H., Özbalak M. M., Yenerel M. N., et al.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis , vol.35, no.6, pp.307-315, 2024 (SCI-Expanded, Scopus) Sustainable Development

11. Sequencing novel agents in the treatment of classical hodgkin lymphoma.

Ferhanoglu B., Özbalak M. M.

Expert review of hematology , 2023 (SCI-Expanded)

12. Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data

Atesoglu E. B., Gulbas Z., UZAY A., ÖZCAN M., ÖZKALEMKAŞ F., Dal M. S., et al.

HEMATOLOGICAL ONCOLOGY , vol.41, no.4, pp.663-673, 2023 (SCI-Expanded)

13. CLL-079 The Effect of T-Lymphocyte Subgroups at Diagnosis on the Prognosis of Chronic Lymphocytic Leukemia (CLL)

Seyithanoglu D., Nazligul E., Ozbalak M. M., Mastanzade M., Erdem S., Nalcaci M., et al.

CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA , vol.23, pp.319-320, 2023 (SCI-Expanded, Scopus)

14. The Effect of T-Lymphocyte Subgroups at Diagnosis on the Prognosis of Chronic Lymphocytic Leukemia (CLL)

Seyithanoglu D., Nazligul E., ÖZBALAK M. M., MASTANZADE M., ERDEM S., NALÇACI M., et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , 2023 (SCI-Expanded)

15. Independent risk factors for COVID-19-associated coagulopathy

Tor Y., Ozbalak M. M., Kalayoglu-Besisik S., Aksoy E., Cagatay A., Gul A., et al.

European Review for Medical and Pharmacological Sciences , vol.27, no.16, pp.7851-7860, 2023 (SCI-Expanded, Scopus) Sustainable Development

16. Salvage Intrapartum Splenectomy for the Treatment of Transfusion-refractory Anaemia in a ß-thalassemia Intermedia Patient.

Sivrikoz T. S., Ozbalak M., Ozmen A., Tukenmez M., Besisik S. K.

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP , vol.32, no.10, pp.1344-1346, 2022 (SCI-Expanded)

17. High expression of OX-40, ICOS, and low expression PD-L1 of follicular helper and follicular cytotoxic T cells in chronic lymphocytic leukemia

Gelmez M. Y., Oktelik F. B., Çınar S., Ozbalak M. M., Ozluk O., Aktan M., et al.

JOURNAL OF HEMATOPATHOLOGY , vol.15, no.3, pp.117-129, 2022 (SCI-Expanded, Scopus)

18. Dipyridamole does not have any additive effect on the prevention of COVID-19 coagulopathy.

Kalayoglu Besisik S., Ozbalak M. M., Tor Y. B., Medetalibeyoglu A., Kose M., Senkal N., et al.

American journal of blood research , vol.12, no.2, pp.54-59, 2022 (Peer-Reviewed Journal) Sustainable Development

19. Biosimilar Rituximab (Redditux) Added to CHOP Chemotherapy for De Novo Diffuse Large B-Cell Lymphoma Patients: Real-Life Single-Center Experience

Özbalak M. M., Güzel Mastanzade M., Özlük Ö., Tiryaki T. O., Erdem S., Özbalak E. P., et al.

TURKISH JOURNAL OF HEMATOLOGY , vol.39, no.4, pp.254-261, 2022 (SCI-Expanded, Scopus, TRDizin)

20. Overview of clinical and genetic features of CML patients with variant Philadelphia translocations involving chromosome 7: A case series

Bayrak A. G., Daglar Aday A., Yavuz A. S., Nalcaci M., Ozbalak M. M., Cefle K., et al.

LEUKEMIA RESEARCH , vol.111, 2021 (SCI-Expanded, Scopus)

21. Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: Multicenter retrospective study.

Akay O. M., Ozbalak M. M., Pehlivan M., Yildiz B., Uzay A., Yigenoglu T. N., et al.

Hematological oncology , vol.39, no.4, pp.498-505, 2021 (SCI-Expanded)

22. Raman tweezers as an alternative diagnostic tool for paroxysmal nocturnal hemoglobinuria.

Soysal K. B., Parlatan S., Mastanzade M., Ozbalak M. M., Yenerel M. N., ÜNLÜ M. B., et al.

Analytical methods : advancing methods and applications , vol.13, no.35, pp.3963-3969, 2021 (SCI-Expanded)

23. R-CHOP Chemotherapy with a Rituximab Biosimilar (Redditux®) for Patients with de novo Diffuse Large B-cell Lymphoma: First Preliminary Results of a Real-Life Single-Center Experience from Turkey

Özbalak M. M., Mastanzade M., Özlük Ö., Tiryaki T. O., Pınar Özbalak E., Yönal Hindilerden İ., et al.

İstanbul Kanuni Sultan Süleyman Tıp Dergisi , vol.13, no.3, pp.194-198, 2021 (TRDizin)

24. Brentuximab Vedotin Consolidation Therapy after Autologous Stem-Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma: Multi-Center Retrospective Study

Ozbalak M. M., Akay O. M., PEHLİVAN M., Yildiz B., UZAY A., Yigenoglu T. N., et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.21, 2021 (SCI-Expanded)

25. KILLER IMMUNOGLOBULINE LIKE RECEPTOR GENE ANALYSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA AND ITS RELATION WITH AUTOIMMUNITY

Ozbalak M. M., Ozunal I. E., Berk S., ELVERDİ T., SALİHOĞLU A., EŞKAZAN A. E., et al.

JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESI DERGISI , vol.84, no.2, pp.227-236, 2021 (ESCI)

26. Initial complete blood count score and predicting disease progression in COVID-19 patients.

Ozbalak M. M., Kalayoglu Besisik S., Tor Y. B., Medetalibeyoglu A., Kose M., Senkal N., et al.

American journal of blood research , vol.11, no.1, pp.77-83, 2021 (ESCI) Sustainable Development

27. Initial complete blood count score and predicting disease progression in COVID-19 patients

Ozbalak M. M., Besisik S., Tor Y. B., Medetalibeyoglu A., Kose M., Senkal N., et al.

AMERICAN JOURNAL OF BLOOD RESEARCH , vol.11, no.1, pp.77-83, 2021 (ESCI) Sustainable Development

28. Cytomegalovirus reactivation during adult acute lymphoblastic leukemia maintenance: do we underestimate (un)expected guest of pediatric approach?

Ozbalak M. M., Mastanzade M., GÜREL E., BEŞIŞIK S.

AMERICAN JOURNAL OF BLOOD RESEARCH , vol.11, no.1, pp.118-122, 2021 (ESCI) Sustainable Development

29. Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience

Bekoz H., ÖZBALAK M. M., Karadurmus N., PAYDAŞ S., Turker A., TOPTAŞ T., et al.

ANNALS OF HEMATOLOGY , vol.99, no.11, pp.2565-2576, 2020 (SCI-Expanded)

30. Gıda Kaynaklı İmmünomodülatörler

Kohansal Koshksaray F., Özbalak M. M., Balkan İ. İ., Erten Yurdagül G.

Experimed , vol.10, no.2, pp.97-111, 2020 (Peer-Reviewed Journal) Sustainable Development

31. Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience.

Ozbalak M. M., SALİHOĞLU A., Soysal T., Karadogan I., PAYDAŞ S., Ozdemir E., et al.

Annals of hematology , vol.99, no.2, pp.301-307, 2020 (SCI-Expanded)

32. Retrospective Analysis of Peripheral T-Cell Lymphoma Patients: Single Center 'Real-Life' Experience

Ozbalak M. M., MASTANZADE M., Ozluk O., TİRYAKİ T. O., Hindilerden I. Y., YENEREL M. N., et al.

MEDICAL JOURNAL OF BAKIRKOY , vol.16, no.4, pp.392-398, 2020 (ESCI, Scopus, TRDizin)

33. Bortezomib induced pulmonary toxicity: a case report and review of the literature

Saglam B., Kalyon H., Ozbalak M. M., Ornek S., Keske S., Tabak L., et al.

AMERICAN JOURNAL OF BLOOD RESEARCH , vol.10, no.6, pp.407-415, 2020 (ESCI) Sustainable Development

34. Venetoclax-Rituximab in Chronic Lymphocytic Leukemia

Ferhanoglu B., Ozturk E., ÖZBALAK M. M.

NEW ENGLAND JOURNAL OF MEDICINE , vol.378, no.22, pp.2141-2143, 2018 (SCI-Expanded)

35. Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience.

Bekoz H., Karadurmus N., Paydas S., Turker A., Toptas T., Tuglular T. F., et al.

Annals of oncology : official journal of the European Society for Medical Oncology , vol.28, no.10, pp.2496-2502, 2017 (SCI-Expanded)

36. Inflammatory myofibroblastic tumor mimicking a relapse in a patient with Hodgkin's lymphoma: report of an unusual case and review of the literature.

Özbalak M. M., Torun E. S., ÖZDEMIRLI M., Uçar A. R., Akpınar T. S., Taşçıoğlu C., et al.

Clinical case reports , vol.5, pp.945-949, 2017 (ESCI, Scopus)

37. Use of fluorodeoxyglucose positron emission tomography for diagnosis of bleomycin-induced pneumonitis in Hodgkin lymphoma

Falay O., Ozturk E., Bolukbasi Y., Gumus T., Ornek S., ÖZBALAK M. M., et al.

LEUKEMIA & LYMPHOMA , vol.58, no.5, pp.1114-1122, 2017 (SCI-Expanded)

38. Bronchus Associated Lymphoid Tissue Lymphoma Presenting with Immunodeficiency and Multiple Pulmonary Nodules.

BOREKCI S., OZBALAK M. M., Ersen E., AKı H., CEM A. M., UMUT S.

Case reports in pulmonology , vol.2017, pp.4804378, 2017 (Scopus)

39. Comparison of International Prognostic Index and NCCN-IPI in 324 patients with de novo diffuse large B-cell lymphoma: a multi-center retrospective analysis.

ÖZTÜRK E., ÖZBALAK M. M., Berk S., Erdoğan I., AVŞAR E., DOLGUN A., et al.

Leukemia & lymphoma , vol.57, pp.1211-4, 2016 (SCI-Expanded)

40. Is valganciclovir really effective in primary effusion lymphoma: case report of an HIV(-) EBV(-) HHV8(+) patient.

Ozbalak M. M., TOKATLI I., Ozdemirli M., Tecimer T., Ar M. C., ORNEK S., et al.

European journal of haematology , vol.91, no.5, pp.467-9, 2013 (SCI-Expanded) Sustainable Development

41. An unusual presentation of a chronic lymphocytic leukemia patient with 17p deletion after reduced-intensity transplantation: Richter syndrome and concomitant graft-versus-host disease--case report.

Salihoglu A., Ozbalak M. M., Keskin D., Tecimer T., Soysal T., Ferhanoglu B.

Transplantation proceedings , vol.45, no.7, pp.2845-8, 2013 (SCI-Expanded)

42. Detailed analysis of diffuse large B cell lymphoma patients: a single-center, retrospective study.

Ozbalak M. M., Ar M. C., Tuzuner N., Salihoglu A., Eskazan A. E., Ongoren Aydin S., et al.

ISRN hematology , vol.2013, pp.908191, 2013 (Peer-Reviewed Journal)

43. Azacitidine has limited activity in 'real life' patients with MDS and AML: a single centre experience.

Ozbalak M. M., Cetiner M., Bekoz H., Atesoglu E. B., Ar C., Salihoglu A., et al.

Hematological oncology , vol.30, no.2, pp.76-81, 2012 (SCI-Expanded)

44. Severe bone marrow failure due to valganciclovir overdose after renal transplantation from cadaveric donors: four consecutive cases.

Ar M. C., Ozbalak M. M., Tuzuner N., Bekoz H., Ozer O., Ugurlu K., et al.

Transplantation proceedings , vol.41, no.5, pp.1648-53, 2009 (SCI-Expanded) Sustainable Development

45. Primary cutaneous T-cell lymphomas other than mycosis fungoides and primary cutaneous CD30(+) lymphoproliferative disorders

Ozbalak M. M., Demirkesen C., Oguz O., Onsun N., Tuzuner N.

VIRCHOWS ARCHIV , vol.451, no.2, pp.456, 2007 (SCI-Expanded)

46. Prognostic significance of micro vessel density in diffuse large B cell lymphomas

Soer M., Ozbalak M. M., Senocak M., Soysal T., Ferhanoglu B., Molinas N., et al.

VIRCHOWS ARCHIV , vol.451, no.2, pp.357-358, 2007 (SCI-Expanded)

Papers Presented at Peer-Reviewed Scientific Conferences 35

1. Yüksek Riskli Hematoloji Hastasında QT Uzaması ve Ekstrapiramidal Etkiler Açısından İlaç Etkileşimlerinin Değerlendirmesi ve Yönetimi

Arı A., Erdal M., Usta T., Özbalak M. M., Yönal Hindilerden İ., Alp Yıldırım F. İ., et al.

Marmara Üniversitesi Eczacılık Fakültesi Ulusal Eczacılık Kongresi, İstanbul, Turkey, 8 - 10 May 2025, pp.207-208, (Summary Text)

2. Chimerism Monitoring with Next- GenerationSequencing: Identification of Microchimerism BeyondSTR

Ögret Y., Çınar Ç., Özbalak M. M., Yönal Hindilerden İ., Oğuz F.

38th EFI Conference Immunogenetics , Praha, Czech Republic, 14 - 17 May 2025, pp.46-47, (Summary Text)

3. The Silent Threat of Secondary Malignancies in Multiple Myeloma Patients: A Cohort Study from Turkey in the Era of New Drugs

Mastanzade M., Taha F. J., Hasanzade U., İnan N. Y., Zeynallı B., Ören Çelik M. M., et al.

The 11th World Congress on CONTROVERSIES IN MULTIPLE MYELOMA (COMy), Paris, France, 15 May 2025, (Summary Text)

4. A Single-Center Real-Life Experience with First-Line Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (DARA-VCD) in AL Amyloidosis

MASTANZADE M., ÖREN ÇELİK M. M., ERDEM S., ÖZBALAK M. M., YÖNAL HİNDİLERDEN İ., YENEREL M. N., et al.

Hematoloji Uzmanlık Derneği 18. Ulusal Kongresi, Antalya, Turkey, 21 - 24 November 2024, vol.46, pp.26-27, (Summary Text)

5. AL Amiloidozda Karaciğer Tutulumunun Sessiz İzleri: Fibroscan Yol Gösterir mi?

MASTANZADE M., DAĞCI G., ÖREN ÇELİK M. M., ERDEM S., ÇAVUŞ B., SAKCI E., et al.

50. ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Turkey, 29 October 2024, pp.185, (Summary Text)

6. Akut Miyeloid Lösemide İzositrat Dehidrogenaz 1 (IDH1) Gen Mutasyonu Sıklığı ve Klinik: Tek Merkez Deneyimi

ÇATMA Y., ERDEM S., ADAY A., MASTANZADE M., ÖZBALAK M. M., YÖNAL HİNDİLERDEN İ., et al.

50. ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Turkey, 29 October 2024, pp.228, (Summary Text)

7. The Effect of T-Lymphocyte Subgroups at Diagnosis on the Prognosis of Chronic Lymphocytic Leukemia (CLL)

SEYİTHANOĞLU D., Nazlıgül E., ÖZBALAK M. M., MASTANZADE M., ERDEM S., NALÇACI M., et al.

Proceedings of the Society of Hematologic Oncology 2023 Annual Meeting, Houston, United States Of America, 6 - 09 September 2023, (Summary Text)

8. Büyük granüllü lenfosit artışı olan olguların tanısında immünfenotiplemenin rolü: Tek merkez deneyimi

NAZLIGÜL SERT E., TİRYAKİ T. O., ÖZBALAK M. M., MASTANZADE M., ÖZLÜK D. Ö., ERDEM S., et al.

48. ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Turkey, 01 November 2022, pp.199-200, (Summary Text)

9. Kronik lenfositer lösemi olgularının tanı sırasındaki T lenfosit alt gruplarının prognoz üzerine etkisi

SEYİTHANOĞLU D., NAZLIGÜL SERT E., ERDEM S., ÖZBALAK M. M., MASTANZADE M., ÖZLÜK D. Ö., et al.

48. ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Turkey, 01 November 2022, pp.145-146, (Summary Text)

10. Multipl miyelom dışı plazma hücre hastalıklarında kök hücre desteği ile yüksek doz kemoterapi deneyimi

TİRYAKİ T. O., YÖNAL HİNDİLERDEN İ., ERDEM S., MASTANZADE M., ÖZBALAK M. M., OLUK B., et al.

48. ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Turkey, 01 November 2022, pp.196-197, (Summary Text)

11. Red cell alloimmunization in multi-transfused Turkish patients with hematologic disorders

Öztaşkın S., Yanaşık M., Özbalak M. M., Güzel Mastanzade M., Özlük Ö., Tiryaki T. O., et al.

EHA 2022 Hybrid Congress, Vienna, Austria, 9 - 17 June 2022, pp.2844, (Summary Text)

12. Relationship between HLA and COVID-19 in unrelated bone marrow donors

Erol A., D. Öğret Y., Kıvanç D., Süleymanoğlu M., Özbalak M. M., Beşışık B., et al.

Hacettepe Acta Medica- XVII. Congress of Medical Biology and Genetics, 28 - 31 October 2021, vol.52, pp.407-408, (Summary Text)

13. Kemik iliği bağışçılarında HLA ve COVID-19 ilişkisi

EROL A., Öğret Y., KIVANÇ D., SÜLEYMANOĞLU M., ÖZBALAK M. M., Beşışık B., et al.

XVII.Tıbbi Biyoloji ve Genetik Kongresi, 28 October 2021, vol.52, pp.407-408, (Summary Text) Sustainable Development

14. WHAT HAVE WE EXPERIENCED WITH COVID-19 IN PATIENTS WITH HEMATOLOGICAL DISORDERS?

ERDEM S., MASTANZADE M., ÖZBALAK M. M., KUBİLAY D. Ö., TİRYAKİ T. O., OLUK B., et al.

XIIth Eurasian Hematology-Oncology Congress, İSTANBUL (Hibrit Kongre), Turkey, 10 November 2021, vol.43, pp.96, (Summary Text)

15. ASPARAGINASE INDUCED SINUS VEIN THROMBOSIS IN AN ADULT YOUNG ALL PATIENT

OLUK B., KUBİLAY D. Ö., ÖZBALAK M. M., ERDEM S., BEŞIŞIK S.

XIIth Eurasian Hematology-Oncology Congress, İSTANBUL (Hibrit Kongre), Turkey, 10 November 2021, vol.43, pp.77, (Summary Text)

16. Yeni tanı DBBHL’de biyobenzer rituksimab (Redditux) içeren R-CHOP rejimi sonuçları: Tek merkez gerçek yaşam deneyimi

ÖZBALAK M. M., MASTANZADE M., KUBİLAY D. Ö., TİRYAKİ T. O., ERDEM S., Pınar Özbalak E., et al.

47. Ulusal Hematoloji Kongresi, Antalya, Turkey, 04 November 2021, (Full Text)

17. R-CHOP Chemotherapy Including Biosimilar Rituximab (Redditux) for De-Novo Diffuse Large B-Cell Lymphoma Patients: Real-Life Single Center Experience

Özbalak M. M., Mastanzade M., Özlük Ö., Tiryaki T. O., Erdem S., Özbalak E. P., et al.

63rd ASH Annual Meeting and Exposition, Georgia, United States Of America, 11 - 14 December 2021, pp.4585, (Summary Text)

18. A Case of Congenital Afibrinogenemia with Two Successful Spontaneous Delivery after Recurrent Pregnancy Losses

Mastanzade M., Özbalak M. M., Beşışık S.

ISTH 2021 Congress, Pennsylvania, United States Of America, 17 - 21 July 2021, no.5, pp.312, (Summary Text)

19. Increased activity of follicular helper T and cytotoxic T cellsin chronic lymphocytic leukemia

Gelmez M. Y., Öktelik F. B., Çınar S., Özbalak M. M., Deniz G.

6th European Congress of Immunology (ECI 2021), Belgrade, Serbia, 1 September - 04 October 2021, pp.1, (Summary Text)

20. Increased activity of follicular helper T and follicular cytotoxic T cells in Chronic Lymphocytic Leukemia

Gelmez M. Y., Öktelik F. B., Çınar S., Özbalak M. M., Özlük Ö., Deniz G., et al.

6th European Congress of Immunology, Belgrade, Serbia, 1 - 04 September 2021, pp.245, (Summary Text)

21. Dual-Beam optical Manipulation of Red blood cells for the investigation of paroxysmal nocturnal hemoglobinuria

Parlatan U., Soysal K. B., Parlatan S., Mastanzade M., Ozbalak M. M., Yenerel M. N., et al.

Optical Manipulation and Its Applications, OMA 2021 - Part of Biophotonics Congress: Optics in the Life Sciences 2021, Virtual, Online, United States Of America, 12 - 16 April 2021, (Full Text)

22. A raman tweezer study with single red blood cells for the diagnosis of paroxysmal nocturnal hemoglobinuria

Parlatan S., Parlatan U., Soysal K. B., Mastanzade M., Ozbalak M. M., Yenerel M. N., et al.

Optical Molecular Probes, Imaging and Drug Delivery, OMP 2021 - Part of Biophotonics Congress: Optics in the Life Sciences 2021, Virtual, Online, United States Of America, 12 - 16 April 2021, (Full Text)

23. BAŞVURU ANI TAM KAN SAYIMI PUANLAMASININ COVID-19 HASTALARINDA İLERLEYİCİ HASTALIĞI GÖSTERMEDE ROLÜ

ÖZBALAK M. M., BEŞIŞIK S., TOR Y. B., MEDETALİBEYOĞLU A., KÖSE M., Şenkal N., et al.

46. Ulusal Hematoloji Kongresi, Turkey, 28 - 31 October 2020, (Summary Text)

24. Prognostic value of pre-treatment neutrophil-lymphocyte and platelet-lymphocyte ratio in diffuse large B-cell lymphoma: a single-center experience

Dağcı G., Mastanzade M., Özbalak M. M., Kubilay D. Ö., Tiryaki T. O., Yönal Hindilerden İ., et al.

XIth Eurasian Hematology Oncology Congress, İstanbul, Turkey, 21 - 24 October 2020, no.42, pp.48-49, (Summary Text)

25. FUSARİUM SPP İLE SİNOPULMONER İNFEKSİYON: HEMATOLOJİK MALİGNİTELERDE İKİNCİ SIKLIKTA KÜF MANTARI İNFEKSİYONU

ÖZLÜK SEVEN Ö., OLUK B., ÖZBALAK M. M., SOLTANOVA L., ALTUNOK D., YILMAZ E., et al.

46. ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Turkey, 28 - 31 October 2020, pp.177-178, (Full Text)

26. Dipyridamole Added to Anticoagulant Prophylaxis: Decline in Poor Outcome of Clinically Severe Ill COVID-2019 Patients

BEŞIŞIK S., ÖZBALAK M. M., TOR Y. B., MEDETALİBEYOĞLU A., KÖSE M., Şenkal N., et al.

International Society on Thrombosis and Hemostasis Annual Congress 2020, 12 - 14 July 2020, (Summary Text)

27. A relapsed refractory CD30 positive cutaneous anaplastic large cell lymphoma with large B-cell transformation responding to brentuximab vedotin after multiple lines of treatment.

Erdem S., Özbalak M. M., Baykal C., Kalayoğlu Beşışık S.

Xth International Eurasian Hematology Oncology Congress, İstanbul, Turkey, 8 - 11 October 2019, pp.560, (Summary Text)

28. A retrospective analysis of peripheral T-cell lymphoma patients: single-center 'real-life' experience

Ozbalak M. M., Besisik S., Mastanzade M., Ozluk O., Ozmen A., Hindilerden I. Y., et al.

10th Eurasian Hematology Oncology Congress, İstanbul, Turkey, 8 - 11 October 2019, vol.85, (Summary Text)

29. Role of [Ga-68]-pentixafor-PET/CT as a novel imaging of cxcr4 expression in multiple myeloma; comparison to [F-18]-FDG-PET/CT

Tiryaki T. O., Kuyumcu S., Has-Simsek D., Ozbalak M. M., Ozluk D., Unal S., et al.

10th Eurasian Hematology Oncology Congress, İstanbul, Turkey, 8 - 11 October 2019, vol.85, (Summary Text)

30. A relapsed refractory CD30 positive cutaneous anaplastic large cell lymphoma with large B-cell transformation responding to brentuximab vedotin after multiple lines of treatment

Erdem S., Ozbalak M. M., Baykal C., Besisik S.

10th Eurasian Hematology Oncology Congress, İstanbul, Turkey, 8 - 11 October 2019, vol.85, (Summary Text)

31. Role of [68Ga]-pentixafor-PET/CT as a novel imaging of cxcr4 expression in multiple myeloma comparison to [18F]-FDG-PET/CT

TİRYAKİ T. O., KUYUMCU S., HAS ŞİMŞEK D., ÖZBALAK M. M., KUBİLAY D. Ö., ÜNAL S. N., et al.

Xth International Eurasian Hematology-Oncology Congress, İstanbul, Turkey, 8 - 12 October 2019, vol.85, (Summary Text)

32. Long-Term Results of Brentuximab Vedotin in Relapsed and Refractory Hodgkin Lymphoma: Multi-Center Real-Life Experience

Ferhanoglu A. B., ÖZBALAK M. M., SALİHOĞLU A., Soysal T., Karadogan I., Paydas S., et al.

59th Annual Meeting of the American-Society-of-Hematology (ASH), Georgia, United States Of America, 9 - 12 December 2017, vol.130, (Summary Text)

33. NIVOLUMAB FOR RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: EXPERIENCE IN TURKEY

Ferhanoglu B., Bekoz H., Karadurmus N., Paydas S., Gulbas Z., Turker A., et al.

22nd Congress of the European-Hematology-Association, Madrid, Spain, 22 - 25 June 2017, vol.102, pp.84-85, (Summary Text)

34. IS FDG-PET THE MOST SENSITIVE TOOL TO DIAGNOSE BLEOMYCIN INDUCED PNEUMONITIS IN HODGKIN'S LYMPHOMA?

Ozturk E., Falay O., Bolukbasi Y., Gumu T., Ornek S., ÖZBALAK M. M., et al.

10th International Symposium on Hodgkin Lymphoma, Cologne, Germany, 22 - 25 October 2016, vol.101, pp.43, (Summary Text)

35. The comparison of up-front autologous peripheral stem cell transplantation in first remission and long-lasting intensive chemotherapy protocols in highly aggressive non-Hodgkin's lymphomas: Results of a retrospective analysis.

Ozturk M., Ozaydin S., Oyan B., Ozbalak M. M., Arpaci F., Paydas S., et al.

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30, (Summary Text)

Metrics

Publication

Publication (WoS)

Publication (Scopus)

Citation (WoS)

164

H-Index (WoS)

Citation (Scopus)

195

H-Index (Scopus)

Citation (Scholar)

H-Index (Scholar)

Citation (Sobiad)

H-Index (Sobiad)

Project

Open Access

UN Sustainable Development Goals

Publications & Works

Publication

Publication (WoS)

Publication (Scopus)

Citation (WoS)

H-Index (WoS)

Citation (Scopus)

H-Index (Scopus)

Citation (Scholar)

H-Index (Scholar)

Citation (Sobiad)

H-Index (Sobiad)

Project

Open Access